🔗 Share this article

While the US proceeds with sweeping revisions to its vaccine recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 shots in the pandemic and has concentrated on potential deaths after COVID-19 immunization in her brief tenure at the FDA.

Proposed Changes to Childhood Immunization Schedule

Public health authorities planned to unveil radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a major change that would put the US at odds with much of the world with no evidence for public health gain. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Høeg is set to present at the event. She was recently named interim head of the FDA’s CDER, the fifth individual to head the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific childhood immunization guidelines in the US to become more like Denmark, a society with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Background

Dr. Høeg has little discernible track record in pharmaceutical research, oversight or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She is not an expert in drug approvals.”

Previous heads of the center would “understand regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Frankly, she lacks the type of experience that previous people who led CBER have had.”

This division has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“The public just focuses on the new drug program, but the off-patent medication office authorizes a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be looked after,” Woodcock explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant leadership aspect to the position, which manages over 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official said.

Agency Reaction and Disputed Policies

When asked about inquiries about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “concerns are based on inaccurate assumptions”.

“Her resume aligns with the responsibilities of her job,” the official stated, citing the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's controversial priority voucher program, a contentious expedited therapy clearance system that apparently worried her former heads. “By what process are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, except for shots.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, history, some experts said. She released a analysis using non-validated crowd-sourced reports to determine the rate of myocarditis after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “desired changes” for the new government included altering rules for new vaccines and discontinuing “optional” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of preventing young men from receiving COVID-19 vaccines.

“She is an thorough true believer who starts off with her beliefs and works backwards to accommodate the evidence in a very deceptive, fraudulent manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|